BPC-157 and TB-500: two different ideas of repair

Two peptides sit on the same shelf and share a rumour. Body protection compound-157 is a fifteen-residue fragment of a gastric protein, proline-rich, stubborn in acid, and studied for three decades as a cytoprotective and angiogenic probe. TB-500 is a laboratory analogue built around the LKKTETQ actin-binding motif of thymosin β4, the principal G-actin sequestering peptide of animal cells. They got glued into a pair because both showed up in injury models and both were short enough to lyophilise. Biochemistry didn't glue them. One talks, on the cleaner papers, to a receptor tyrosine kinase and to focal-adhesion kinase. The other parks actin monomers so a cell can push a lamellipodium — a sheet of filament at the leading edge. If you can't tell those jobs apart, you aren't yet running an experiment. You're repeating a pairing. This catalogue keeps both vials because both literatures are real, and keeps them apart because the literatures are not one literature.

In short. Two short peptides get sold as a pair. One comes from a stomach protein. The other helps cells crawl by holding spare actin. They are not the same job.

Repair, when you sit down to measure it, isn't a mood. It's a named tissue, a named insult, a named readout, and a clock. Gastric lesion area after indomethacin. Load-to-failure of a tendon-to-bone junction at six weeks. Tenocyte outgrowth from an explant. Endothelial migration across a scratch in eight hours. Re-epithelialisation of an alkali-burned cornea. Collagen birefringence under polarised light. Those are assays. Healing is the word a brochure reaches for when it doesn't want to name the assay. This piece names the two molecules, the two literatures, the two reasons a bench might open either vial, and the reasons it shouldn't open them as if they were one reagent with two labels. We stock both. We characterise both. We refuse the pair as a scientific object. If you can't name the insult, the tissue and the clock, you aren't yet measuring repair, however pretty the caption.

In short. Repair in a lab is a named test: a stomach ulcer in a rat, a cut in a dish, a tendon under load. A brochure word for healing is not an assay.

Sequence is identity. BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, written GEPPPGKPADDAGLV, mass 1419.5 daltons, CAS 137525-51-0. Thymosin β4 is a forty-three-residue, intrinsically disordered peptide whose actin-binding hexapeptide is Leu-Lys-Lys-Thr-Glu-Thr-Gln. Research TB-500, as the trade analogue is usually sold, orbits that motif; full-length Tβ4 is a different object, and the N-terminal tetrapeptide Ac-SDKP is a third. HPLC-MS is how you know which of those three you reconstituted. A nickname on a cap is how you pretend you already know. The rest of this piece is what the named sequences actually do, what a single-laboratory programme in Zagreb built over thirty years, what Goldstein and Safer and Huff established about a thymic peptide that turned out to be a cytoskeletal buffer, and how a blot tells the two stories apart. A certificate without a mass is a label. A label isn't a ligand. No protocol. The papers that already ran the models are in PubMed.

In short. A peptide is its amino-acid sequence and its mass. BPC-157 is fifteen residues. Thymosin β4 is forty-three. The lab certificate, not a nickname, says which one you have.

Body protection compound was the name Predrag Sikiric's group in Zagreb gave to a proteinaceous activity in human gastric juice that cytoprotected mucosa against a catalogue of insults. BPC-157 is the synthetic pentadecapeptide they took from that work and put into print, from the early 1990s, as a stable fragment that still did the job. The origin story matters because it's chemistry, not branding. Most fifteen-mers die in the stomach. Pepsin cuts after hydrophobic residues; pH 1.5 unfolds anything that was relying on a salt bridge; the transit time is hours. A peptide that can be gavaged into a rat and still move a gastric-lesion endpoint has already told you something about its backbone. Proline is the residue that does most of that telling. Four prolines in fifteen positions, clustered toward the amino end, starve several proteases of a comfortable cut site and stiffen the chain against the acid unfold. That's why oral rodent studies exist at all. They aren't a marketing claim about bioavailability in a person. They're a consequence of a proline-rich 15-mer that gastric juice itself selected.

In short. BPC-157 is a fifteen-amino-acid piece of a stomach protein. It survives acid because it is full of proline. That is why rat studies could even give it by mouth.

The gastric juice protein from which the fragment was taken isn't a hormone in the Bayliss and Starling sense, neither secretin nor gastrin, and it doesn't occupy a class-B GPCR on a pancreatic cell and raise cAMP. It's a cytoprotective peptide activity that a laboratory in Croatia chose to synthesise as a 15-mer and then spent a career dropping into every injury model the animal house would support. That career is the Sikiric corpus, and it's both the reason the molecule is famous and the reason we keep a pencil in hand. Hundreds of papers, one principal investigator as a constant, a recurring nitric-oxide theme, and a spread of endpoints that would make a multi-centre consortium blush. The useful way to read a literature that large and that concentrated isn't to throw it out and isn't to swallow it. It's to ask which pieces independent labs have reproduced, which pieces remain in-house, and which pieces wandered so far from the stomach that the original chemical reason for the peptide has been left behind.

In short. This is not a gut hormone like the ones that tell the pancreas to release insulin. It is a stomach-derived fragment a Croatian lab spent decades testing in injury models.

Fifteen residues is a short protein and a long peptide. Insulin is fifty-one. GLP-1 is thirty or thirty-one depending on the amide. A GPCR ligand of this length usually has a defined fold and a receptor pocket it evolved to occupy. BPC-157 has no solved globular structure worth hanging a mechanism on. It's Pro-rich, acidic in the middle (two aspartates), and hydrophobic at the carboxyl end. People have docked it, in silico, against VEGFR2 and against various extracellular matrix proteins, and docking a floppy 15-mer is a way to generate a colourful figure, not a way to generate a Kd. The experimental engagements that have survived contact with other laboratories are cruder and better: endothelial cells migrate; VEGFR2 is internalised and phosphorylated; focal-adhesion kinase and paxillin light up; nitric-oxide tone in a vessel or a gut wall moves as if a set-point had been restored rather than as if a donor had been poured in. Those are phosphorylation blots and organ-bath traces. They aren't a crystal.

In short. Fifteen amino acids is short, and this chain does not fold like insulin. The useful evidence is cell movement and phosphorylation, not a computer picture of it sitting on a receptor.

Mass 1419.5. Formula C62H98N16O22 if you write the free peptide; the lyophilised cake on a certificate will also report trifluoroacetate or acetate counter-ions depending on the cleavage and the salt exchange, and it's worth writing which. Purity ≥98% HPLC is a peak, not a physiology. A deletion peptide missing one glycine can hide under a cheap UV trace and still wreck an assay, which is why the interesting chromatogram is the one with a mass on it, not the one with a pretty single peak at 214 nanometres. We synthesise the named 15-mer. We put the sequence and the mass on the certificate. We don't put a healing percentage on it, because a healing percentage isn't a property of a pentadecapeptide. It's a property of a model, a dose, a clock, and a control group someone else already ran, in a named tissue.

In short. The chain weighs about 1,420 daltons. A lab certificate should show the mass and a clean peak. That still does not tell you what it does in a living animal.

Pepsin is an aspartic protease with a preference for aromatic and hydrophobic residues, optimally active around pH 2. A peptide rich in proline and poor in phenylalanine and tyrosine is already a bad substrate. The three consecutive prolines in GEPPP… are a local polyproline stretch; they don't adopt an alpha helix, they don't present a classic scissile bond, and they make the amino-terminal half of the 15-mer look, to a protease, like a problem. Gastric lipase and the subsequent tryptic and chymotryptic gauntlet in the duodenum are the next tests. Oral gavage studies in rats reported gastric-lesion protection at microgram-to-milligram doses, which is only possible if a useful fraction of the chain is still the chain when it meets the mucosa. Parenteral studies exist too, and they're a different pharmacokinetic object. Conflating gavage in a rodent with a capsule in a person is how a stability fact becomes a wellness claim. The fact remains: this 15-mer was selected, historically, because the stomach did not destroy it. That's a rare sentence in peptide chemistry. It's also the entire reason the molecule escaped the gastroenterology literature and walked into tendon papers.

In short. Stomach acid and pepsin destroy most short peptides. This one is built so they mostly do not. That is a chemistry fact, not a reason to treat it as a pill.

The gut lining is a sheet of polarised epithelial cells, a mucus layer, tight junctions, a basement membrane, and a lamina propria full of immune cells and a vascular bed that is never more than a few tens of micrometres away. Cytoprotection, in the language Robert and Szabo taught the ulcer field, is the ability of a mucosa to resist injury without a measurable change in acid secretion. Prostaglandins were the first such story; misoprostol is the licensed descendant. BPC-157 entered that conversation as a non-prostaglandin cytoprotectant, and the Zagreb papers on NSAID gastropathy, alcohol lesions, and bile-reflux models are the original dataset. Independent groups have been thinner on the gastric endpoint than on the endothelial one, which is already a clue about how the literature aged. A peptide that protects a mucosa might do so by keeping epithelium stuck to basement membrane, by keeping blood flow, by damping an inflammatory burst, or by all three. Blood flow is the sentence that leads, almost immediately, to nitric oxide and to endothelium, and endothelium is the sentence that leads to VEGFR2. The stomach was the door. The vessel was the room.

In short. The gut lining is a thin living wall with tight seals and a rich blood supply. Early papers asked whether this peptide helped that wall resist injury. Blood flow became the next question.

Once a stable peptide talks to endothelium, the rest of the injury catalogue is almost inevitable. A tendon-to-bone junction is a vascular and a collagen problem. A crushed muscle is a vascular and a myofibre and a fibrosis problem. A colon anastomosis is a vascular and a leak problem. A cornea isn't a gut, but it is an epithelium on a stroma with a migration clock. The Zagreb group put the 15-mer into all of those, and into a few places a sceptical reader wouldn't have started: nigrostriatal lesions, behavioural despair, inflammatory bowel models that sit next to the original mucosa, periodontal defects. Breadth is a scientific virtue when each model is independently replicated. Breadth is a warning light when one laboratory is the constant and the endpoints multiply faster than the mechanistic papers. I still think the gastric and vascular and tenocyte pieces are the ones a new bench should start with. They're closest to the chemistry that made the peptide interesting, and they're the pieces other people have actually run.

In short. Once a peptide talks to blood-vessel cells, labs try it in tendon, muscle and gut repairs. Some of those tests have been repeated outside the original group. Many have not.

Predrag Sikiric, University of Zagreb School of Medicine, and a rotating cast of colleagues (Seiwerth, Sikirić, Kokić, Drmić, Starešinić — the names recur) built, from about 1993, one of the largest preclinical peptide corpora in print. The early papers sit in Journal of Physiology and Pharmacology, Journal of Orthopaedic Research, Burns, Digestive Diseases and Sciences, and a long tail of specialty journals that will take an injury model. The through-line they themselves emphasise is organoprotection: a peptide that restores a physiological set-point after an insult, rather than a peptide that simply stimulates a receptor. The nitric-oxide system is the set-point they named most often. L-NAME makes lesions worse; L-arginine can make them better; BPC-157, in their hands, nudges the animal back toward the middle from either side. That's an unusual pharmacological claim. It's also a claim that demands, and has not always received, a dose–response, an eNOS phosphorylation blot, and an outside laboratory with no reason to protect the hypothesis. The claim is interesting enough to keep. It isn't yet a closed mechanism.

In short. A Zagreb group spent thirty years testing this peptide in many injury models. They argue it resets nitric-oxide tone rather than simply raising it. That claim is interesting and still needs outside checks.

NSAID gastropathy is the original neighbourhood. Indomethacin, diclofenac, aspirin: cyclo-oxygenase inhibition, prostaglandin collapse, a mucosa that can no longer keep its mucus and bicarbonate and blood flow, lesions that a pathologist scores by area. Robert's cytoprotection was prostaglandin replacement. Sikiric's argument was that BPC-157 reduced lesion area in these models without being a prostaglandin, and that the protection reached intestinal and liver injuries that NSAIDs also cause. Those papers are numerous. They're also, as a body, light on randomisation detail and on the sort of blinding a modern ulcer paper would insist on. That isn't a reason to invent a conspiracy. It's a reason to treat effect sizes as provisional and to look for the groups that ran an NSAID lesion with a characterised 15-mer and a pre-registered scoring rule. The scientific value of the gastric work, for a peptide catalogue, isn't a human ulcer claim. It's the chemical fact that a 15-mer survived the organ that invented it, plus a pile of rodent lesion scores that a careful lab could re-run.

In short. The first papers were about stomach damage from anti-inflammatory drugs. The peptide seemed to shrink those lesions in rats. The studies are many, and the methods are not always as tight as a modern trial.

Tendon-to-bone is the paper a sports-medicine thread actually wants. Chang, Tsai, Lin, Hsu and Pang, Journal of Applied Physiology 2011: pentadecapeptide BPC-157 promoted tendon outgrowth, cell survival and cell migration in a rat Achilles model, with FAK and paxillin implicated in the tenocyte. Starešinić and the Zagreb group ran transected Achilles and quadriceps defects, load-to-failure, collagen organisation, and a vascular density in the repair bed that is the angiogenic half of the same story. A tendon heals slowly because it is poorly vascularised and because the collagen has to be laid in the line of force, not as a scar. Anything that persuades tenocytes to migrate, survive, and pull on a matrix, and that persuades a capillary to enter the defect, will move those endpoints in a rodent. Whether the 15-mer does that by VEGFR2, by FAK, by a nitric-oxide effect on the vessel, or by some combination, is the mechanistic question the better papers try to close with inhibitors. A caption that says BPC heals tendons has skipped the inhibitor, the clock, and the species.

In short. In rats, the peptide has been reported to help tendon cells crawl, survive and organise collagen, and to bring in small vessels. That is a rodent finding with named assays, not a sports protocol.

Muscle crush is the third Zagreb staple. A mechanical insult, a haematoma, a myofibre necrosis, a satellite-cell response, a fibrosis if the clock runs wrong. Papers from that group report faster restoration of function, better fibre organisation, and again a vascular component. Crush is a dirty model, which is both its virtue and its vice: it looks like an injury a person might recognise, and it confounds everything at once. A clean myoblast migration assay in a dish, with the peptide characterised and a FAK inhibitor on the next well, is the experiment that would make a muscle claim mechanistic. Some of that work exists. Not enough of it exists outside the original laboratory. The pattern is now familiar, and it will keep being familiar: the in-vivo phenotype is large and repeated in-house; the molecular paper that would make a biochemist relax is thinner and later. That's how a single-lab programme ages, and it isn't unique to Zagreb. It is what happens when a compound is interesting, cheap to synthesise, and more fun to drop into a new injury than to sit with one blot until the kinase is named.

In short. Crushed muscle in a rat is a messy injury, and the original lab reported faster recovery. Messy injuries are hard to interpret. A clean cell-migration test would do more to name the job.

The NO-reset claim deserves its own paragraph because it's the one mechanistic idea the corpus keeps returning to, and because nitric oxide is a real, named, assayable gas. Endothelial nitric-oxide synthase makes NO from L-arginine; NO activates soluble guanylate cyclase; cGMP relaxes smooth muscle; blood flow rises. Too little NO, and a mucosa or a tendon graft is ischaemic. Too much, and you have hypotension and a different pathology. L-NAME inhibits NOS; L-arginine feeds it. Sikiric's group reported that BPC-157 counteracted both L-NAME and L-arginine derangements in lesion models, which is the reset. Independent endothelial papers have shown eNOS-dependent effects without always signing up to the two-sided reset. Hsieh, Liu, Wang and colleagues, Journal of Molecular Medicine 2017, tied BPC-157 to VEGFR2 activation and internalisation in endothelium, with downstream Akt and eNOS phosphorylation — a one-sided, angiogenic, RTK-shaped story that a Western lab can pick up without buying the entire organoprotection philosophy. That's how you want a large corpus to age: a few nodes other people can occupy, and a surrounding philosophy you are free to leave on the shelf.

In short. The original group says the peptide restores nitric-oxide balance from both directions. Outside labs more often show a blood-vessel growth path through a named receptor. Both can be measured.

How a single-laboratory programme ages is a sociology of science before it is a verdict on a peptide. Effect sizes stay large. Journals stay specialised. Reviewers are often colleagues in the same injury field. Negative results, if they exist, are quieter. None of that is fraud; all of it is how academic careers work when a compound is yours. The correction, which the field already knows how to apply, is independent replication of the pieces that would change a biochemist's week. Angiogenic and tenocyte-migration findings have had more of that correction than the more extravagant central-nervous-system claims — nigrostriatal protection, antidepressant-like behaviour, a wandering into models that a 15-mer from gastric juice had no particular chemical reason to enter. A peptide can have more than one job. It cannot have every job. When I sit with this literature I keep the stomach, the vessel, the tendon, and the NO blot. I put the CNS papers in a pile labelled interesting, unreplicated, and not the reason the 15-mer is on a research shelf.

In short. One lab publishing for decades will look bigger than it is. Other labs have repeated the blood-vessel and tendon-cell pieces more cleanly than the brain claims.

Independent laboratories did not reproduce the entire Zagreb map, and nobody honest expected them to. What they did reproduce, in endothelium and in tendon fibroblasts, is enough to keep the 15-mer interesting as a probe. VEGFR2 phosphorylation and internalisation. Endothelial migration in a scratch or a Boyden chamber that a VEGFR2 inhibitor can blunt. Tenocyte outgrowth and a FAK–paxillin blot. Some anastomotic and fistula papers from groups adjacent to Zagreb. That's a real, if still preclinical, object. It's also a much smaller object than the healing-peptide story that grew up around it. The gap between those two objects is the gap this piece exists to keep open. Collapsing the gap would be selling a pairing we don't think is biochemistry. The 15-mer on the shelf is GEPPPGKPADDAGLV, HPLC-characterised, the sequence those papers named. The papers are public. The blot is yours.

In short. Other groups have repeated the vessel-cell and tendon-cell findings. That is enough to keep the molecule interesting. It is not the same as the larger healing story around it.

VEGFR2 is KDR, Flk-1, a receptor tyrosine kinase. It isn't a GPCR. Seven-helix receptors, G proteins, arrestin, cAMP — that's a different superfamily, and this catalogue uses it for incretins and ghrelin mimetics and melanocortins. VEGFR2 is a single-pass transmembrane protein with an extracellular immunoglobulin-like ligand domain and an intracellular kinase. VEGF-A dimers it; the kinase domains autophosphorylate; PLCγ, PI3K–Akt, Src, and a FAK neighbourhood are among the effectors; endothelial survival, migration and proliferation follow. Internalisation of VEGFR2 isn't merely turning the receptor off. Endocytic traffic of VEGFR2 is part of how the angiogenic signal is shaped, and Hsieh's BPC-157 paper sits on that traffic: the pentadecapeptide associated with VEGFR2 activation and internalisation, with Akt and eNOS downstream. You can disagree with a figure. You can't relabel an RTK as a GPCR because the rest of the catalogue is GPCRs. The second-messenger diagram still earns a place here, because Akt, eNOS and nitric oxide are an amplification cascade. They're just not a Gs cascade.

In short. The blood-vessel receptor named in the cleaner papers is an enzyme in the membrane, not the seven-helix locks most catalogue peptides use. Downstream, kinases and nitric oxide still amplify the signal.

Internalisation is a trafficking sentence. Ligand binds, the receptor clusters, clathrin or a non-clathrin path pulls a vesicle, endosomes sort the cargo for recycling or for lysosomal destruction, and some signalling continues from the endosome. For VEGFR2, the endosomal chapter isn't optional reading. Papers from the VEGF field — not the BPC field — spent years showing that where the receptor sits after the ligand arrives changes which effectors it sees. If a 15-mer promotes VEGFR2 internalisation and phosphorylation, the experiment that follows isn't a testimonial. It is: does a kinase-dead VEGFR2, or SU5416, or a VEGFR2 siRNA, take the endothelial migration with it? Hsieh's group used inhibitors. A new bench should use them too, and should put the characterised peptide on a mass spectrometer before the first well is seeded. VEGFR2 antibodies on a blot are cheap. Time is the expensive part, and identity first is how you spend it well.

In short. When that receptor is pulled inside the cell, the growth signal can still run. The honest test is whether blocking the receptor also blocks the cell movement you think the peptide caused.

Focal-adhesion kinase is the other named node, and it is how a tendon paper and an endothelium paper can share a kinase without sharing a tissue. FAK sits at integrin clusters where a cell grips extracellular matrix. Autophosphorylation at Tyr397 recruits Src; paxillin and p130Cas are phosphorylated; Rac and the actin machinery are told that the grip is real and that a protrusion may proceed. Chang's tenocyte work put FAK and paxillin on the BPC-157 page. Endothelial migration uses the same adhesion kinase because crawling is crawling. A peptide that lights FAK in two cell types is not therefore a universal repair juice. It's a peptide that may feed a kinase two cell types already use to move. The blot is phospho-FAK, phospho-paxillin, a FAK inhibitor (PF-573228 is the one people reach for), and a scratch that should stall when the kinase is blocked. If the scratch doesn't stall, FAK was a spectator, and you've learned something the paper you are citing did not.

In short. A cell uses this kinase to know it is gripping the surface it wants to crawl on. Tendon cells and vessel cells both use it. Block it to see if the peptide needed it.

eNOS is endothelial nitric-oxide synthase, phosphorylated at Ser1177 by Akt among other kinases, and that phosphorylation is a standard Western readout of an angiogenic or shear-stress programme. NO then is the gas: short-lived, locally acting, a relaxant of smooth muscle, a modulator of platelet and leukocyte stickiness, a player in VEGF's own vascular-permeability effects. Sikiric's reset language and Hsieh's eNOS phosphorylation can live in the same neighbourhood without being the same claim. One is a two-sided physiological set-point across organ systems. The other is a kinase on a blot in a human umbilical-vein endothelial cell. A new experiment should pick which sentence it is testing. Organ-bath aortic rings, L-NAME, haemoglobin as an NO scavenger, and an eNOS phospho-antibody will do for the vessel. A gastric-lesion score plus L-NAME will do for the mucosa. Doing both and calling them one mechanism is how two measurements get flattened into one caption. We keep them as two different jobs.

In short. A blood-vessel enzyme makes nitric oxide, a short-lived gas that opens vessels. You can measure the enzyme on a blot or the gas by how a vessel relaxes. Pick one question per experiment.

Endothelial migration is the honest assay because it is cheap, visual, and inhibitor-friendly. Seed a monolayer. Wait until it is confluent. Scratch it with a pipette tip. Image at 0, 8, 12, 24 hours. The gap closes by cells crawling, and, if you let it go too long, by proliferation, which is why a mitomycin C arm exists in a careful protocol. Add the peptide at a stated concentration, from a stock whose identity you have confirmed by HPLC-MS, in a medium whose serum content you have written down because serum is a VEGF bath. Put SU5416 or a VEGFR2 blocking antibody in the next well. Put a FAK inhibitor in the one after that. If the 15-mer closes the gap and the inhibitors reopen it, you have a paper. If the 15-mer closes the gap and the inhibitors do nothing, you have a different paper, and you should write it rather than forcing VEGFR2 onto a result that did not ask for it. Either outcome is science. A closed gap and a caption that says healing isn't.

In short. The simple dish test is a scratch in a sheet of vessel cells. Time-lapse the gap. Add blockers of the named receptor or kinase. If the gap still closes, your story was wrong.

Tenocytes are not endothelial cells. They're the fibroblasts of tendon, a lineage that lives in a dense collagen hierarchy, sees load as its growth factor, and migrates poorly compared with a HUVEC. Outgrowth from an explant, as Chang ran it, is a fair assay: a piece of tendon on a dish, cells crawling off, a count, a kinase blot. Load-to-failure of a repaired Achilles is a different assay, biomechanical, weeks later, confounded by every systemic thing a peptide might have done to the animal. Both appear in the BPC-157 tendon literature. Only the first is close to a mechanism. The second is a phenotype, and phenotypes are allowed, but they aren't VEGFR2. A lab that wants the 15-mer as a tenocyte probe should run the explant, the scratch, the phospho-FAK blot, and a collagen gel contraction if they have the patience. A lab that wants a rodent biomechanics paper should budget for the six-week clock and for a surgeon who can make the defect the same way twice. Those are different grants.

In short. Tendon cells are not vessel cells. Watching them crawl off a scrap of tendon is closer to a mechanism than weighing a repaired tendon six weeks later, though both appear in the papers.

TB-500 is a trade name that has been used, carelessly, for more than one chain. Full-length thymosin β4 is forty-three amino acids, acetylated at the N-terminus in the native protein, mass about 4.96 kilodaltons, the principal G-actin sequestering peptide in most mammalian cells. Research material sold as TB-500 has often been an analogue built around the LKKTETQ actin-binding motif, sometimes the motif itself, sometimes a longer fragment, sometimes, if the certificate is honest, the 43-mer. The only adult response to that mess is to read the certificate. Sequence, mass, HPLC purity, the counter-ion. If those lines are missing, you don't have a ligand, you have a rumour in a vial. We stock an actin-binding analogue, sequence and mass on the certificate, so a scratch assay can name what it put in the well. We don't stock a synonym for BPC-157. We don't stock a mystery 5-kDa cake and let you decide, after the fact, which literature you meant.

In short. TB-500 is a trade name, not a single chain. Full thymosin β4 is forty-three amino acids. Some vials are only the actin-binding piece. Read the certificate or you do not know what you pipetted.

LKKTETQ is residues 17–23 of thymosin β4, the principal actin-binding motif identified by peptide-mapping and mutagenesis in the 1990s. Van Troys, Vandekerckhove, and the Hannappel and Safer laboratories did the biochemistry: the motif is necessary for G-actin sequestration; surrounding residues tune affinity; the N-terminal Ac-SDKP is a different pharmacophore entirely. A heptapeptide isn't a 43-mer. It doesn't carry the nuclear-localisation-ish story some Tβ4 papers tell, it doesn't carry the same extracellular signalling literature, and it doesn't generate Ac-SDKP when a prolyl oligopeptidase bites the N-terminus, because it has no such N-terminus. Treating motif, fragment, and full-length protein as one healing peptide is how three pharmacophores become a nickname. A blot can't tell them apart if you never ran the mass. A scratch assay can't tell them apart if you never ran a G-actin binding measurement. Name the chain. Then crawl.

In short. Seven amino acids in the middle of thymosin β4 grab spare actin. That piece is not the whole protein, and it is not the separate anti-scarring fragment at the front end.

The analogue on a research shelf exists because full-length Tβ4 is a more expensive synthesis, a more demanding characterisation, and a molecule whose clinical-adjacent neighbours (the RegeneRx RGN programmes) already occupy a different regulatory and commercial world. A motif-centred analogue lets a migration assay ask whether the actin-binding idea is sufficient for a given phenotype in a dish. Sometimes it will be. Sometimes the phenotype that Sosne saw on a cornea, or that Bock-Marquette saw in a heart, needed the rest of the 43-mer, or needed Ac-SDKP, or needed a cell type that releases endogenous Tβ4 when you injure it and doesn't care what you pipetted. Those are empirical questions. They're the reason you characterise the peptide first and run the assay second. The other order — run the scratch, get a closed gap, then ask the supplier what was in the vial — is how posters get written, and how two labs that think they replicated each other discover, a year later, that they used different chains.

In short. Labs use a shorter analogue because it is simpler to make. Some effects of the full protein may need the rest of the chain. That is an experiment, not a label.

Allan Goldstein isolated the thymosins from thymus in the 1960s and 1970s as putative immune hormones, a family of small acidic peptides of which thymosin α1 and thymosin β4 became the famous ones. The immune-hormone frame was the frame of that decade: thymus as an endocrine gland, peptides as the secretions, immunity as the endpoint. Some of that frame survived. Thymosin α1 went on to a clinical life of its own. Thymosin β4's ageing was more interesting. The protein is abundant in almost every cell, not just in thymocytes; it is one of the most plentiful peptides in a platelet; and the job that survived contact with biochemistry wasn't a hormone receptor. It was actin. Daniel Safer, in 1991, showed that thymosin β4 and Fx, an actin-sequestering peptide, were indistinguishable. A thymic hormone had been a cytoskeletal buffer all along. That's one of the better demotions in peptide history. The molecule got more interesting as it got less mystical.

In short. Thymosin β4 was first pulled from the thymus and treated as an immune hormone. It turned out to be a common cell protein whose real job is holding spare actin.

Huff, Müller, Otto, Netzker and Hannappel wrote the review a cytoskeleton lab actually cites: β-thymosins, small acidic peptides with multiple functions, International Journal of Biochemistry and Cell Biology, 2001. Intrinsically disordered. One-to-one with G-actin. A reservoir that profilin, cofilin and the barbed-end polymerases draw on when a lamellipodium is required. Expression high in platelets, macrophages, wound fluid. Release from dying or activated cells as an extracellular signal that, in later papers, moves VEGF, MMPs and keratinocyte migration. The extracellular chapter is how a G-actin buffer became a repair literature. Inside the cell it is a monomer sponge. Outside, it is a peptide other cells can see. Those are two jobs, and they don't have to share a receptor. The intracellular job is binding actin. The extracellular job is still being mapped, and some of it may be the N-terminal tetrapeptide after a protease cut, which is already a third job. Huff's review is the document. Goldstein's isolation is the history. Safer's identification is the plot twist. A pairing thread is none of those.

In short. Actin biologists treat this protein as a monomer sponge inside the cell. Outside, it can also act as a signal. Those two jobs may use different pieces of the chain.

Forty-three residues, acetylated serine at the N-terminus in the native form, a theoretical mass of 4963.5 for Ac-Tβ4, a pI around 5, no disulfide, no fold that a crystallographer would take home. Intrinsically disordered proteins bind by capturing a partner rather than by presenting a pre-formed pocket, and Tβ4:G-actin is a textbook case. The actin monomer is 42 kilodaltons, a nucleotide-binding protein with a pointed and a barbed end conceptually borrowed from the filament. Tβ4 occupies a surface that blocks both ends of the monomer from joining a filament, which is what sequestration means. The Kd is in the micromolar range, matched to the cellular concentration of the peptide, which is also micromolar in many cells. That matching is the biology. A buffer only works if the buffer and the ligand are present at comparable concentrations. Picomolar Tβ4 in a well, against millimolar actin in a cell you just lysed, isn't a sequestration experiment. It's a misunderstanding of scale. Cell Biology by the Numbers is on the next desk for a reason.

In short. The full protein is small, floppy, and present at high concentration inside cells, one copy per spare actin molecule. A tiny dose in a dish is not the same physics as the cell's own store.

Injury releases it. Platelets dump their contents into a wound; macrophages arrive; damaged cells leak. Extracellular Tβ4 has been reported to induce VEGF expression, to raise MMP-2, to send keratinocytes migrating, and to modulate inflammatory tone. Malinda, Goldstein and Kleinman, FASEB Journal 1997, showed directional migration of human umbilical-vein endothelial cells toward Tβ4. That paper is why an actin-buffer peptide sits in an angiogenesis paragraph without being VEGF. The cell crawls because its actin is being told to. The cell also crawls because a peptide in the medium is being read as a cue. Both can be true in one well. Distinguishing them is the point of a G-actin binding mutant: an LKKTETQ-disrupted Tβ4 that should lose sequestration but might keep an extracellular phenotype, or vice versa. Those mutants exist in the literature. They're the experiment a motif-only analogue is half-way toward, and also the experiment a motif-only analogue cannot finish, because a motif isn't a mutant of a 43-mer. It's a different molecule.

In short. When tissue is damaged, this protein spills out of platelets and cells. Other cells then migrate toward it. That outside-the-cell job is related to, but not identical with, holding actin inside.

Cardiac repair is the paper that took Tβ4 out of the wound-fluid literature and put it on a Nature cover-adjacent page. Bock-Marquette, Saxena, White, Dimaio and Srivastava, Nature 2004: thymosin β4 activates integrin-linked kinase, promotes cardiac cell migration and survival, and, in a coronary-ligation model, improves survival and reduces scarring. Integrin-linked kinase is another focal-adhesion neighbourhood protein, which is how a cytoskeletal buffer and a heart-injury phenotype can share a sentence without sharing BPC-157's VEGFR2. Subsequent cardiac papers argued about pinocytosis, about epicardial progenitors, about whether the effect was on existing cardiomyocytes or on a repair population. The argument is what a Nature paper is for. Full-length Tβ4 is the ligand those experiments used. A motif analogue in a lyophilised cake isn't automatically that ligand. If your cardiac explant study wants Srivastava's molecule, synthesise or buy the 43-mer, confirm the mass, and write Tβ4 in the methods. If it wants the actin-binding idea in a fibroblast scratch, the analogue is a lawful tool. You pick in the write-up, not after the gap has closed.

In short. A 2004 Nature paper used the full protein in a heart-injury model and named a different adhesion kinase. That experiment used the forty-three-amino-acid chain, not a short analogue.

Corneal repair is Sosne's neighbourhood. Alkali injury, a standard ophthalmic insult, a re-epithelialisation clock, an inflammatory score, a scar. Thymosin β4 promoted corneal wound healing and decreased inflammation after alkali injury in vivo (Experimental Eye Research, 2002, and a run of follow-ups). The eye is a fair organ for a migration peptide: a sheet of epithelium that must crawl, a stroma that must not scar into opacity, a clinical endpoint a slit lamp can see. RegeneRx's RGN-259 programme took a Tβ4 ophthalmic formulation into human studies; RGN-137 was the dermal neighbour. Mixed readouts, not empty ones, and a reminder that the cytoskeletal programme is, in principle, drug-able. Those programmes used characterised full-length Tβ4 in a formulated product. They're the clinical-adjacent neighbour of the research analogue, and they aren't the analogue. Citing a Phase 2 ophthalmic study as evidence for a motif peptide in a scratch assay is a category error. Citing it as evidence that actin-buffer biology can reach a person is a fair historical sentence.

In short. Eye-injury papers and some human ophthalmic studies used the full protein as a formulated product. That is a neighbour of the research analogue, not a substitute for naming the chain in your dish.

Ac-SDKP is N-acetyl-seryl-aspartyl-lysyl-proline, the N-terminal tetrapeptide of Tβ4, generated physiologically by prolyl oligopeptidase. It's an anti-fibrotic and angiogenesis-modulating peptide with an ACE-adjacent literature: angiotensin-converting enzyme degrades Ac-SDKP, ACE inhibitors raise it, and some of the anti-fibrotic benefit of ACE inhibitors has been argued to run through this tetrapeptide. Carretero's group spent years on that axis. Ac-SDKP isn't an actin sequesterer. It doesn't carry LKKTETQ. Lumping it with motif-only TB-500 and with 43-aa Tβ4 under one healing-peptide label is how a literature gets garbled into a pair. Three pharmacophores, three assays. G-actin binding for the motif. Hydroxyproline and collagen I for the tetrapeptide's anti-fibrotic claim. The full 43-mer when your model is Sosne's cornea or Srivastava's heart. A certificate that can't tell you which of those three you reconstituted has already failed, before any cell was seeded. Keep the three names on three tubes.

In short. A four-amino-acid piece snipped from the front of thymosin β4 has its own anti-scarring papers. It does not bind actin. Treat it as a third molecule, not a nickname.

Actin treadmilling is the physics of a crawl. Monomers add to the barbed (plus) end of a filament and leave from the pointed (minus) end. In a lamellipodium the barbed ends face the membrane; polymerisation pushes; cofilin and tropomyosin and myosin help the rear keep up; adhesion complexes grip so the push becomes locomotion rather than blebbing. Pollard, Borisy, Theriot, and a generation of reconstituted motility papers made this a textbook cycle. Thymosin β4's place in the cycle is the reservoir: a pool of G-actin that isn't free to add to barbed ends until a GEF, a profilin exchange, or a local drop in Tβ4 occupancy releases it. Profilin-actin is the form the barbed end actually wants. Cofilin severs and feeds the pool. Arp2/3 nucleates branches. Formins nucleate unbranched cables. The peptide doesn't replace any of those machines. It holds the spare parts. A cell that cannot sequester G-actin has a noisy, poorly timed polymerisation. A cell that cannot release G-actin cannot push. The buffer is interesting because injury, and a handful of extracellular cues, change how much of it is available, and where.

In short. Cells crawl by adding actin building blocks at the front of a filament and taking them off at the back. Thymosin β4 holds the spare blocks until the front needs them.

Lamellipodia are the broad, sheet-like protrusions of a migrating cell; filopodia are the spikes. Both are actin. A scratch assay scores, crudely, whether lamellipodia closed a gap. A more honest assay scores protrusion rate, focal-adhesion turnover, and the G/F-actin ratio by centrifugation or by a fluorescent reporter. Tβ4 shifts that ratio toward G. A motif analogue should do the same if it sequesters, and should fail to do the same if the well contains a chain that never bound actin. That's the blot-level distinction this essay keeps promising: not an antibody against a brand name, a biochemical activity. DNase I inhibition, pyrene-actin polymerisation, a pull-down with biotin-actin. Those assays were old when the analogue got a trade name. They still work. Running a scratch without them is how you generate a phenotype you can't attribute. Running them without HPLC-MS is how you attribute a phenotype to the wrong chain. The order is identity, activity, then the prettier picture of cells crawling into a gap.

In short. The broad ruffles at the front of a moving cell are actin sheets. Watch them close a gap, or measure whether the peptide grabbed actin. Measure first.

A buffer isn't a growth factor. VEGF is a growth factor: a ligand, a receptor, a transcriptional and a migratory programme, a concentration in the picomolar-to-nanomolar range that a cell is built to notice. Tβ4 inside a cell is a stoichiometric partner of actin, present at tens to hundreds of micromolar in some cytoplasms. Those concentration regimes don't overlap, and they shouldn't be written as if they did. Extracellular Tβ4 may be closer to a cue, and the VEGF-induction papers sit there, at nanomolar-to-micromolar doses in medium, which is already a different physics from the intracellular buffer. A motif analogue at an arbitrary microgram-per-millilitre in a well isn't automatically either regime. Dose, medium, cell type, and a G-actin binding measurement are how you find out which regime you are in. People skip that because a closed scratch is prettier than a pyrene curve. Prettier isn't a mechanism. The motor of the crawl is actin. The peptide, at best, is one of the clerks who decide how many monomers are free to join.

In short. A growth factor is a rare signal a cell is built to notice. The actin-holding protein is abundant spare parts. Those jobs do not share a dose or a receptor.

BPC-157 and TB-500 got bundled because both had large, positive, preclinical injury literatures, both were short enough to synthesise on a solid-phase rig, both were unlicensed, and both photographed well as a pair. Tendon threads wanted a vessel peptide and a crawl peptide and didn't want to learn two mechanisms. A pair of lyophilised cakes with similar reconstitution instructions is a commercial object. It isn't a biochemical object. There's no heterodimer. There's no shared receptor. There's no paper in which a defined molar ratio of GEPPPGKPADDAGLV and LKKTETQ was the independent variable and a named kinase the dependent one. Phenotype rhyme — both look like repair in a rodent — is the weakest reason to co-administer two ligands, and the most common. We've watched that rhyme travel for years. One talks to VEGFR2 and FAK. The other parks actin. If a blot can't tell them apart, they shouldn't be in the same well until the blot can.

In short. People paired them because both showed up in injury stories and both were easy to vial. Shared rumour is not a shared receptor. No paper makes them one drug.

Phenotype rhyme is a recurring failure mode around this catalogue. GHK-Cu also sits in a repair neighbourhood, as a copper-binding tripeptide with a fibroblast transcriptome. KPV sits in a barrier-inflammation neighbourhood, a melanocortin tripeptide with a PepT1 uptake story. GLOW, on the shelf, is those ideas lyophilised together with BPC-157 and TB-500 so a bench that wants four named sequences doesn't open four caps. That's a logistics decision. It isn't a claim that copper delivery, actin sequestration, VEGFR2 traffic and a PepT1 cargo share a pathway. A blend is a convenience. A stack, in the pairing language, is a protocol. We'll sell the convenience to a laboratory that can name the four chains. We won't launder it into a protocol. The same sentence applies to the two-peptide pair this essay is about. Related in folklore. Unrelated in mechanism. Stocked as two certificates, and, if someone insists, as part of a four-sequence cake whose label still lists the four sequences.

In short. Other repair-adjacent peptides exist too, including a copper tripeptide and a barrier tripeptide. Putting them in one vial is a packing choice. It does not make them one pathway.

There's a softer reason the pairing stuck, and it isn't entirely foolish. A wound bed needs a vessel and a crawling cell. Angiogenesis without migration is a leaky granulation tissue. Migration without a blood supply is a sheet that dies in the middle. Combining an angiogenic probe with a cytoskeletal probe is, as a hypothesis, the sort of thing a tumour biologist already knows from VEGF plus integrin papers. The hypothesis is lawful. The leap from hypothesis to a fixed pair of research peptides, at folkloric ratios, in the absence of a factorial experiment, isn't. The factorial is: BPC-157 alone, TB-500 alone, both, neither, on a named readout, with identity confirmed. Until that figure exists in a paper you trust, the pair is a rhyme. I'd rather a bench ran the factorial once than a hundred threads repeated the rhyme. The vials will still be here in the morning. The factorial is the work.

In short. A healing wound does need both new vessels and crawling cells, so pairing the ideas is a fair hypothesis. It is still a hypothesis until someone tests each peptide alone and both together.

Mass first. BPC-157 at 1419.5 daltons cannot be mistaken for a 5-kDa Tβ4 analogue on a mass spectrometer, and a motif heptapeptide is smaller still. If the certificate already has the mass, repeat it on the reconstituted stock, because lyophilised peptides are hygroscopic, labels smudge, and the tube you think is the 15-mer is, in a crowded freezer, sometimes the other tube. HPLC second, not as a purity performance but as a peak you can collect and put back on the mass spec if the assay misbehaves. Antibody third, and only if you trust the antibody. Anti-Tβ4 antibodies exist; they won't see BPC-157. Anti-BPC-157 antibodies are rarer and should be treated as guilty until a spike-in and a knockout-or-preabsorption control say otherwise. Phospho-VEGFR2, phospho-FAK, phospho-eNOS, and a G/F-actin ratio are the activity blots. They don't identify the peptide. They identify a cellular response. A response without an identity is a story about the well, not about the ligand.

In short. Weigh the chain on a mass spectrometer first. The stomach peptide and the actin peptide cannot hide as each other. Activity blots then tell you what the cells did, not what you added.

Orthogonal readouts are how you stop lying to yourself. For the 15-mer: a VEGFR2 phosphorylation that a VEGFR2 inhibitor abolishes; an endothelial scratch that SU5416 reopens; an eNOS Ser1177 blot; perhaps an aortic-ring relaxation that L-NAME blunts. For the actin analogue: a pyrene-actin polymerisation curve that shifts as a sequesterer should; a G/F ratio; a scratch that a cytoskeletal poison (latrunculin, at a dose you have titrated) interprets; a motif mutant or a scrambled peptide as the negative ligand. If both peptides close a scratch, and only one of those orthogonal sets moves, you've learned that a scratch is a low-specificity endpoint. Which it is. Fibroblasts close scratches because you fed them, because the density was wrong, because the pipette tip released a wound signal, because a peptide did something interesting. The blot panel is how you find out which. Running both peptides in the same scratch without the panel is the pairing experiment, and it will give you the pairing result: both worked. Of course they did. Gaps close.

In short. Use different tests for each peptide: vessel-signal tests for one, actin-binding tests for the other. If both close a gap but only one set moves, the gap test was too easy.

A Western is a denatured protein on a membrane, an antibody, a peroxidase, a film or a digital imager. It isn't magic, and it isn't identity. Phospho-antibodies report a pool, not a pathway, until the inhibitor arm is there. Loading controls report that you put similar protein in each lane, not that the biology was similar. Quantification of WES or of film by densitometry is a religion with two sects, and I won't referee it except to say: show the blot, show the n, show the inhibitor. For actin, a Western for Tβ4 can confirm the peptide entered a lysate; it cannot confirm sequestration. For BPC-157, there is often nothing to Western but the downstream kinases, because a 15-mer may not have an antibody you trust. Mass spectrometry of the medium, before and after the incubation, will tell you whether the 15-mer survived the well. Peptides disappear. Proteases in serum, adsorption to plastic, a pH you didn't measure. A disappearing ligand is a classic way to generate a negative result that the molecule didn't earn, or a positive one that belongs to a fragment you never named.

In short. A blot shows a protein the antibody can see, not the peptide you think you added. Measure the peptide in the dish at the end. Short chains vanish into plastic and enzymes.

Identity, then activity, then phenotype. That order is the whole write-up. HPLC-MS of the cake. HPLC-MS of the reconstituted stock. A concentration you actually measured, not a nominal microgram-per-millilitre from a label that assumed the cake was dry and the balance was true. Vehicle matched: acetic acid, TFA residual, bacteriostatic water, whatever you used, in the control wells at the same volume. Serum stated, because serum is ligands. A cell type that has the machinery you claim — HUVECs for VEGFR2, primary tenocytes or a decent tendon line for FAK, a keratinocyte or corneal epithelial line if you are in Sosne's neighbourhood, a platelet lysate if you are talking about released Tβ4. Species stated, because a rat VEGFR2 isn't a human VEGFR2 and a milligram figure isn't a nanomolar occupancy in a well. Then the inhibitor. Then the n. Then the thing you actually wanted to photograph. Reverse that order and you will photograph something. You won't know what it was.

In short. First prove what is in the tube, then prove it does the chemistry you claim, then take the pretty picture. Reverse that order and you only have a picture.

Dose is where folklore does its worst work. In-vitro endothelial papers that named VEGFR2 used nanomolar-to-micromolar BPC-157, which is a lawful range for a peptide against a receptor if the Kd lives there, and we don't, in public, have a clean Kd. In-vivo rodent papers used micrograms to milligrams per kilogram, by gastric gavage or by injection, on clocks from hours to weeks. Tβ4 cardiac and corneal papers used their own microgram-range local doses. Collapsing those into a single human milligram figure is a unit conversion that physics didn't authorise. A research well should start at a log series around the concentrations the paper you are replicating actually used, and should include a zero and a toxic high. If the phenotype only appears at a concentration that detaches the monolayer, you have a detergent, not a ligand. If it appears at one point on the curve and vanishes on either side, you may have a real pharmacology, and you should be happy, because biphasic curves are how a lot of honest peptide biology looks. Write the curve. Don't pick the point that flattered the hypothesis.

In short. Papers use very different amounts in a dish and in an animal. Copy the range from the paper you are repeating, include a zero, and do not keep only the dose that looked nicest.

Species and sex and age aren't footnotes. A young male Sprague-Dawley rat with a transected Achilles is the animal a lot of the tendon papers used. An ovariectomised female, an aged animal, a diabetic animal, a different species, will move the same endpoints differently, and the Sikiric corpus sometimes did those variants and sometimes did not. Endothelial cells from human umbilical vein are a foetal, venous, proliferative population that isn't a tendon capillary and isn't an adult artery. They're still the workhorse if you say so. Primary tenocytes lose phenotype in culture; passage number belongs in the write-up. Corneal epithelium in a dish isn't a tear film. None of this is a reason to stop. It's a reason to stop writing as if a HUVEC scratch were a person. The jump from a well to an organism is the jump the clinical Tβ4 programmes actually tried to make, with mixed results. The 15-mer hasn't made that jump in a literature I'd put next to those programmes. Preclinical is a class of evidence. It isn't a small human trial that someone forgot to publish.

In short. Rat tendons, human umbilical-vein cells and a living person are different systems. Say which one you used. A dish result is real and still not a human study.

Controls are the part a reviewer can still save. Scrambled peptide, same mass, different sequence. Heat-inactivated peptide, if the activity should be sequence-specific and not a contaminant. Vehicle. Inhibitor. A positive control that must work or the week is void: VEGF for an endothelial scratch, serum for a fibroblast, a known sequesterer for a pyrene-actin curve. Blinded scoring of lesion area and of biomechanical testing, because those endpoints are where hope enters the callipers. Pre-registration if you are in a world that offers it. At minimum, a written analysis plan before the first blot, so that the phospho-antibody you added on Friday isn't the one that 'worked'. I know this sounds preachy. I also know how many peptide papers, including some I otherwise like, skipped two of those controls and still got through peer review. The analogue and the 15-mer will survive contact with a proper control. If they don't, they weren't what the caption said, and that's a result worth publishing.

In short. Include a scrambled chain, the liquid without peptide, a drug that should block the effect, and a treatment you already know works. If those are missing, the figure is a draft.

Repair, for BPC-157, is a cytoprotective and angiogenic idea that escaped a stomach. A proline-rich 15-mer survived acid, talked to mucosa, and then, on the papers a biochemist can run, talked to VEGFR2 and to FAK in endothelium and tenocytes, with an eNOS-dependent nitric-oxide tone that the Zagreb group would like you to read as a reset. Repair, for TB-500, is a cytoskeletal idea that escaped a thymus. A disordered 43-mer turned out to be the cell's G-actin sponge; injury spilled it; lamellipodia spent it; an analogue around LKKTETQ put that sponge on a certificate. Those are two ideas. They rhyme at the level of a wound bed, which needs a vessel and a crawling cell. They don't rhyme at the level of a receptor, a kinase, a monomer, or a mass spectrum. Folklore stacked them because rhyme is easy. A catalogue that kept them as two vials is doing the only interesting thing a catalogue can do, which is to refuse to flatten two literatures into one caption.

In short. One peptide is a stomach fragment that talks to vessel and tendon cells. The other holds actin, from a thymic protein. A wound might need both jobs. That does not make them one molecule.

The neighbouring essays on this desk take the two molecules apart. BPC-157: the pentadecapeptide that survived the stomach — gastric cytoprotection, the Zagreb corpus, the VEGFR2 node, at catalogue length for the 15-mer alone. TB-500 and thymosin β4: repair is a cytoskeletal programme — Goldstein, Safer, Huff, Sosne, Bock-Marquette, Ac-SDKP as a third pharmacophore. This piece is the joint, and the joint is a distinction. Read them in any order. Don't read them as a protocol. GHK-Cu sits in an adjacent room with copper and a fibroblast array. KPV sits in a barrier room with PepT1. The living-cell essays — occupancy and amplification, actin as a city-scale object, the gut as a wall — are the physics underneath both vials. A research peptide is a few nanometres of chain. The cell it meets is a packed interior with ten billion proteins. Scale was always the point. The pair was always a way of not looking at scale.

In short. Separate essays cover each peptide on its own. This one exists to keep them from collapsing into a pair. Read the cell-scale and receptor pieces if you want the physics underneath.

I'm not going to dose. I won't tell you how to combine the vials, how many milligrams, how many weeks, or what a person should expect from a rodent tendon. Those sentences are protocols, and protocols for unlicensed peptides belong in a different kind of document. The papers that already ran the models wrote their methods: gavage or injection, species, clock, endpoint. Go there if you're running an experiment. Stay here if you wanted the two ideas distinguished. Both listings are lyophilised research peptides, HPLC-characterised, labelled for laboratory use only. They are neither medicines nor a stack. They are two probes, and the blot is how you tell which probe you are holding. Research use only, once, at the close, as the legal class of the reagent — not as a refrain in the physiology, which was always the interesting part.

In short. This is not a dosing guide and not a medicine. Both vials are lab reagents with certificates. The interesting part was always which job each chain can do.